The Valley Desk

Clinical trial reportCancerPublished

Intratumoral vidutolimod as monotherapy or in combination with pembrolizumab in patients with programmed cell death 1 blockade-resistant melanoma: Final analysis from a phase 1b study

Read the publication ↗ Open access copy ↗

Regional connection

Verified Author affiliations on the Europe PMC record name Fox Chase Cancer Center, Thomas Jefferson University, with Temple Health linked by the institution reference. Affiliation source

Publication record

Type
Clinical trial report
Venue
Cancer
Published
Subject terms
Humans; Melanoma; Skin Neoplasms; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Adult; Aged; Aged, 80 and over; Middle Aged; Female; Male; Antibodies, Monoclonal, Humanized
PubMed ID
40753466
PubMed Central ID
PMC12318270
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal